Financial Performance - The company's operating revenue for Q1 2025 was ¥1,725,715,319.77, a decrease of 13.68% compared to ¥1,999,261,196.40 in the same period last year[3] - Net profit attributable to shareholders was ¥12,517,312.95, down 57.99% from ¥29,792,564.09 year-on-year[3] - The net profit after deducting non-recurring gains and losses was ¥8,483,951.04, a decline of 69.79% compared to ¥28,084,784.36 in the previous year[3] - The basic earnings per share decreased by 55.56% to ¥0.0016 from ¥0.0036 in the same period last year[4] - The diluted earnings per share fell by 66.67% to ¥0.0012 from ¥0.0036 year-on-year[4] - The weighted average return on net assets was 0.0674%, down from 0.1545%, a decrease of 0.0871 percentage points[4] - Total operating revenue for Q1 2025 was ¥1,725,715,319.77, a decrease of 13.7% compared to ¥1,999,261,196.40 in Q1 2024[16] - Net profit for Q1 2025 was ¥7,535,116.90, a decline of 72.2% from ¥27,143,210.75 in Q1 2024[17] - Total comprehensive income for Q1 2025 was ¥22,040,365.17, down from ¥28,631,801.49 in Q1 2024[17] Assets and Liabilities - Total assets at the end of the reporting period were ¥29,844,949,250.05, an increase of 0.66% from ¥29,649,734,539.88 at the end of the previous year[4] - The company's current assets totaled CNY 13.88 billion, down from CNY 14.00 billion at the end of 2024, with cash and cash equivalents at CNY 7.12 billion[12] - Accounts receivable increased to CNY 880.41 million from CNY 809.76 million, reflecting a growth of approximately 8.7%[12] - The company's inventory rose to CNY 4.67 billion, compared to CNY 4.54 billion, indicating an increase of about 2.5%[12] - Total liabilities increased to CNY 11.12 billion from CNY 10.64 billion, representing a growth of approximately 4.4%[14] - The company's long-term borrowings rose significantly to CNY 1.66 billion from CNY 766.44 million, indicating a substantial increase[14] - The equity attributable to shareholders decreased slightly to CNY 18.47 billion from CNY 18.63 billion, a decline of about 0.8%[14] Cash Flow and Investments - Cash flow from operating activities for Q1 2025 was negative at -¥54,591,408.70, an improvement from -¥433,373,338.57 in Q1 2024[20] - Cash inflow from investment activities in Q1 2025 totaled ¥30,851,147.38, compared to ¥4,911,030.97 in Q1 2024[20] - The net cash flow from investing activities was -$338.08 million, compared to -$239.70 million in the previous period, indicating an increase in cash outflow for investments[21] - Cash inflow from financing activities totaled $2.28 billion, up from $1.53 billion, reflecting a significant increase in borrowing[21] - The net cash flow from financing activities was $605.02 million, compared to $419.36 million in the previous period, showing improved cash generation from financing[21] - The cash and cash equivalents at the end of the period amounted to $7.07 billion, an increase from $2.65 billion at the end of the previous period[21] - The company reported a total cash outflow from investing activities of $368.93 million, compared to $244.61 million previously, indicating increased investment activity[21] - The cash outflow for debt repayment was $1.32 billion, significantly higher than $517.69 million in the previous period, reflecting a focus on reducing debt[21] - The net increase in cash and cash equivalents for the period was $214.13 million, a recovery from a decrease of -$253.78 million in the previous period[21] Projects and Future Plans - The company is advancing several major projects, including the completion of the Guang'an project and the initiation of AI control in experimental setups[9] - The company aims to achieve high-phosphorus and high-silicon phosphate rock sales from the Wonarah project in Australia within the year[9] - The company has outlined plans for the Nigeria mining rights cooperation project, targeting scientific and intelligent mining practices to commence in May 2025[9] Expenses and Impairments - Research and development expenses for Q1 2025 were ¥4,536,209.31, a decrease of 45.4% from ¥8,346,347.48 in Q1 2024[16] - The company reported a significant increase in tax expenses, with Q1 2025 tax expenses at ¥13,108,894.20 compared to ¥16,465,391.27 in Q1 2024[17] - The company experienced a credit impairment loss of -¥7,366,037.14 in Q1 2025, an improvement from -¥14,527,656.52 in Q1 2024[16]

Financial Performance - In 2024, the company's operating revenue was approximately CNY 8.55 billion, a decrease of 3.13% compared to CNY 8.82 billion in 2023[25]. - The net profit attributable to shareholders was CNY 31.46 million, down 97.55% from CNY 1.28 billion in 2023[25]. - The basic earnings per share dropped to CNY 0.0038, a decline of 97.42% from CNY 0.1474 in the previous year[24]. - The net cash flow from operating activities increased significantly to CNY 467.93 million, up 482.50% from CNY 80.33 million in 2023[25]. - The total assets at the end of 2024 were CNY 29.65 billion, an increase of 20.81% from CNY 24.54 billion at the end of 2023[25]. - The company's net assets attributable to shareholders decreased by 4.85% to CNY 18.63 billion from CNY 19.58 billion in 2023[25]. - The company experienced a significant decline in profit margins due to market price reductions for some products, influenced by macroeconomic conditions[26]. - The diluted earnings per share for 2024 was CNY 0.0037, reflecting a decrease of 97.49% from CNY 0.1474 in 2023[26]. - The company reported a quarterly net profit of CNY -189.85 million in Q4 2024, contrasting with profits in the earlier quarters[28]. - Non-recurring gains and losses for 2024 totaled CNY 7.97 million, significantly lower than CNY 47.78 million in 2023[31]. Dividend Policy - The company plans to distribute a total of RMB 161 million in cash dividends for the first half of 2024, with no cash dividends or capital reserve transfers planned for the full year[5]. - The company has no plans for cash dividends or capital reserve transfers for the fiscal year 2024, focusing instead on reinvestment for growth[5]. - The company has a clear cash dividend policy that aligns with its articles of association and protects minority shareholders' rights[183]. - The cumulative cash dividend amount over the last three accounting years is approximately 553 million RMB, with an average cash dividend ratio of 32.40% of the average net profit[188]. - The net profit attributable to ordinary shareholders for the most recent accounting year is approximately 31.46 million RMB[188]. - The company has not proposed any cash profit distribution plan for 2024, citing compliance with its profit distribution policy and future development needs[182]. Project Development and Investment - The company is currently developing several projects, including a 500,000-ton glyphosate project in Guang'an and a 200,000-ton glyphosate project in Indonesia, which are critical for future revenue growth[8]. - The company plans to accelerate the construction of three phosphate mining projects, aiming for a total production capacity of over 4 million tons per year within 1-2 years[38]. - The company has signed an agreement with AFRICORP HOLDINGS LIMITED to jointly develop 22 lithium mines and 6 tin mines in Nigeria, with detailed exploration set to start in May 2025[38]. - The company has successfully completed the issuance of convertible bonds totaling RMB 460 million, with funds earmarked for the investment and construction of a 500,000 tons per year glyphosate project[45]. - The company is advancing the Wonarah phosphate project in Australia, aiming for high-phosphorus and high-silica phosphate rock sales within the year[43]. - The company has increased its R&D investment in both the chemical and mining sectors, emphasizing process technology innovation[36]. - The company aims to leverage the current low prices of raw materials and services to significantly reduce project investment costs[42]. Market Conditions and Pricing - The company reported that its product gross margin is significantly affected by market price fluctuations, indicating potential volatility in financial performance[8]. - The company emphasizes the importance of market conditions and policy changes on raw material prices, which could affect production costs and profitability[8]. - The price of glyphosate fluctuated between RMB 24,000 and RMB 25,000 per ton during the reporting period, experiencing a "high then low" trend[51]. - The domestic phosphate rock market is expected to maintain a tight supply-demand balance, with long-term price stability anticipated due to resource scarcity[47]. - The overall decline in revenue was primarily attributed to falling product prices across various sectors[94]. Operational Efficiency and Workforce - The company has hired 184 new employees in the mining sector, with 30% holding university degrees, laying a foundation for future development[39]. - The company has introduced 18 expert-level talents in the mining sector, enhancing its technical capabilities in exploration and processing[82]. - The company has a diverse workforce with 3,571 production personnel, 190 sales personnel, 801 technical personnel, 72 financial personnel, and 752 administrative personnel[177]. - The company offers a salary policy that includes a base salary plus performance-based pay, encouraging employee development through special allowances and internal competition mechanisms[178]. Environmental and Compliance - The company has been recognized as a key pollutant discharge unit by local environmental authorities, emphasizing its commitment to environmental protection and sustainable development[197]. - The company has implemented a comprehensive wastewater treatment system, ensuring compliance with environmental regulations through centralized treatment and monitoring[197]. - The company has established a robust internal control system, with no significant deficiencies reported during the period[192]. - The company’s internal control effectiveness was audited by an external firm, resulting in a standard unqualified opinion[193]. - All emissions are within the limits set by the respective discharge permits and standards[199][200]. Governance and Management - The company continues to adhere to the insider information management system as per regulations, ensuring compliance with governance standards[160]. - The company has not engaged in any related party transactions that would affect its independence[160]. - The company has scheduled multiple shareholder meetings throughout 2024, with the first one on February 19, 2024[160]. - The company has not reported any requests for temporary shareholder meetings from preferred shareholders[162]. - The company is focused on improving its governance structure through amendments to its articles of association and meeting rules[169].

| 证券代码：603077 | 证券简称：和邦生物 | 公告编号：2025-015 | | --- | --- | --- | | 债券代码：113691 | 债券简称：和邦转债 | | 四川和邦生物科技股份有限公司 关于 2024 年度拟不进行利润分配的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 鉴于四川和邦生物科技股份有限公司（以下简称"公司"）已于 2024 年 10 月实施了 2024 年半年度利润分配，结合公司未来发展规划和资金需求，公司 拟定的 2024 年度利润分配方案为：不进行现金分红，不实施公积金转增股本。 ● 本次利润分配方案尚需提交公司 2024 年年度股东大会审议。 ● 公司未触及《上海证券交易所股票上市规则》第 9.8.1 条第一款第（八） 项规定的可能被实施其他风险警示的情形。 一、利润分配方案内容 经四川华信（集团）会计师事务所（特殊普通合伙）审计，公司 2024 年度 实现的归属于上市公司股东的净利润为 31,464,685.07 元，截至 2024 年 12 月 ...

和邦生物：公司拟终止分拆所属子公司武骏光能至上交所主板上市工作，并撤回相关上市辅导材料。 ...

| 证券代码：603077 | 证券简称：和邦生物 | 公告编号：2025-011 | | --- | --- | --- | | 债券代码：113691 | 债券简称：和邦转债 | | 四川和邦生物科技股份有限公司 关于"和邦转债"开始转股的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ●转股价格：2.00 元/股 ●转股期起止日期：2025 年 5 月 6 日至 2030 年 10 月 27 日（原定转股起始 日 2025 年 5 月 1 日为法定节假日，根据《四川和邦生物科技股份有限公司向不 特定对象发行可转换公司债券募集说明书》（以下简称"《募集说明书》"）约 定，顺延至下一个交易日，即为 2025 年 5 月 6 日） 一、可转债发行上市概况 经中国证券监督管理委员会（以下简称"中国证监会"）证监许可[2024]1233 号同意注册，四川和邦生物科技股份有限公司（以下简称"公司""本公司"） 于 2024 年 10 月 28 日向不特定对象发行了 4,600 万张可转换公司债券，每张面 值 1 ...

| 概念 | 今日涨跌幅（%） | 概念 | 今日涨跌幅（%） | | --- | --- | --- | --- | | 供销社 | 3.93 | 中国AI 50 | -2.09 | | 跨境支付(CIPS) | 3.65 | 人形机器人 | -1.59 | | 草甘膦 | 3.57 | 英伟达概念 | -1.48 | | 中韩自贸区 | 3.16 | 同花顺果指数 | -1.38 | | 自由贸易港 | 3.05 | 算力租赁 | -1.32 | | 统一大市场 | 2.74 | 液冷服务器 | -1.28 | | 数字货币 | 2.63 | 华为手机 | -1.22 | | 转基因 | 2.62 | AI手机 | -1.21 | | 信托概念 | 2.33 | MLOps概念 | -1.21 | | 电子身份证 | 2.04 | 太赫兹 | -1.21 | 资金面上看，今日草甘膦概念板块获主力资金净流入1.47亿元，其中，11股获主力资金净流入，7股主 力资金净流入超千万元，净流入资金居首的是中农联合，今日主力资金净流入7446.07万元，净流入资 金居前的还有利尔化学、润丰股份、ST红太阳等，主力资金 ...

| 证券代码：603077 | 证券简称：和邦生物 | 公告编号：2025-010 | | --- | --- | --- | | 债券代码：113691 | 债券简称：和邦转债 | | 四川和邦生物科技股份有限公司 关于提供担保的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 本次担保金额及已实际为其提供的担保余额： 1、公司本次为和邦农科提供的担保金额为 10,000.00 万元； 2、公司本次为和邦磷矿提供的担保金额为 16,000.00 万元； 3、公司本次为涌江实业提供的担保金额为 1,000.00 万元； 4、公司本次为涌江加油站提供的担保金额为 1,000.00 万元； 5、公司本次为重庆武骏提供的担保金额为 15,000.00 万元； （一）担保基本情况 2025 年 3 月 5 日，公司与中信银行股份有限公司成都分行签订《最高额保 证合同》，为公司控股子公司重庆武骏提供担保，保证方式为连带责任保证，合 同所担保的债务本金数额为 15,000.00 万元人民币，保证期间为主合同项下债务 履行期限届满之 ...

2025 年第一次临时股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 | 证券代码：603077 | 证券简称：和邦生物 公告编号：2025-009 | | --- | --- | | 债券代码：113691 | 债券简称：和邦转债 | 四川和邦生物科技股份有限公司 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 (一) 股东大会召开的时间：2025 年 3 月 6 日 (二) 股东大会召开的地点：四川省乐山市五通桥区和邦大数据中心行政 | 1、出席会议的股东和代理人人数 | | | --- | --- | | | 2,346 | | 2、出席会议的股东所持有表决权的股份总数（股） | 324,742,812 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | 4.0727 | | 份总数的比例（%） | | (四) 表决方式是否符合《公司法》及《公司章程》的规定，大会主持情 况等。 本次会议采用现场记名投票与网络投票相结合的表决方式，由四川和邦生物 科技股份有限公司（以下 ...

北京市东城区建国门内大街 26 号新闻大厦 7 层、8 层 电话：010-88004488/66090088 传真：010-66090016 邮编：100005 北京国枫律师事务所 关于四川和邦生物科技股份有限公司 对本法律意见书的出具，本所律师特作如下声明： 1．本所律师仅就本次会议的召集与召开程序、召集人和出席现场会议人员资格、 会议表决程序及表决结果等合法性发表意见，不对本次会议所审议的议案内容及该等议 案所表述的事实或数据的真实性、准确性和完整性发表意见； 2．本所律师无法对网络投票过程进行见证，参与本次会议网络投票的股东资格、 网络投票结果均由上海证券交易所交易系统和互联网投票系统予以认证； 3．本所及经办律师依据《证券法》《证券法律业务管理办法》《证券法律业务执业 1 2025 年第一次临时股东大会的 法律意见书 国枫律股字[2025]A0075号 致：四川和邦生物科技股份有限公司（贵公司） 北京国枫律师事务所（以下简称"本所"）接受贵公司的委托，指派律师出席并见 证贵公司 2025 年第一次临时股东大会（以下简称"本次会议"）。 本所律师根据《中华人民共和国公司法》（以下简称"《公司法》"）、《 ...

● 四川和邦生物科技股份有限公司（以下简称"公司"）控股股东四川和 邦投资集团有限公司（以下简称"和邦集团"）持有公司的股份数量为 1,963,779,103 股，占公司总股本比例 22.24%。截至本公告披露日，和邦集团累 计质押的股份数量为 1,069,000,000 股，占其持股总数比例为 54.44%，占公司 总股本比例为 12.10%。 | 证券代码：603077 | 证券简称：和邦生物 | 公告编号：2025-008 | | --- | --- | --- | | 债券代码：113691 | 债券简称：和邦转债 | | 四川和邦生物科技股份有限公司 关于控股股东部分股份解除质押的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 二、控股股东及其一致行动人累计质押股份情况 截至本公告披露日，和邦集团及其一致行动人贺正刚先生累计质押股份情况 如下： 本次解除质押后,和邦集团暂无将本次解质股份用于后续质押的计划。若和 邦集团未来进行股份质押，公司将根据其质押情况及时履行信息披露义务。 特此公告。 ● ...